Velacur: Providing patients with early detection of liver disease

Oct 25, 2022
Sonic Incytes' Velacur logo. A purple to light blue gradient made up of polkadots.

One in five Canadians have nonalcoholic fatty liver disease (NAFLD), which can lead to liver cirrhosis and cancer. While there are no drugs on the market, NAFLD can often be reversed with lifestyle changes, such as diet and exercise. Sadly, given that there are often no initial symptoms, patients tend to go undiagnosed until they arrive in the emergency room presenting with cirrhosis.

Sonic Incytes is helping to diagnose liver disease early, so that patients can take necessary steps to manage this condition.

Based in Vancouver, BC, Sonic Incytes has introduced an innovative tool to the market called Velacur™, which aids in the clinical management of patients with liver disease.

Sonic Incytes’ proprietary technology was invented by University of British Columbia professors Tim Salcudean and Robert Rohling. Velacur™ uses an external activation board similar to MRI elastography to generate steady state shear waves through the liver that are then measured via a typical ultrasound. Based on the relative mechanical properties of the different tissues, liver stiffness and fat can be easily and quickly quantified.

As part of their Pilot Fund project with INOVAIT, Sonic Incytes has been developing AI software to improve the ease of use of Velacur for medical professionals who may not be ultrasound specialists. Sonic Incytes hopes to ultimately achieve adoption in primary care, where liver assessment could, over time, become the next vital sign; similar to the way that blood pressure and heart rate is monitored at a visit to the doctor’s office.

Velacur could be transformational by aiding in the detection of liver disease well before the condition progresses to an advanced stage, giving patients the opportunity to change lifestyle habits before it’s too late.

INOVAIT’s Pilot Fund provides support for commercialization-focused R&D projects involving the integration of AI into image-guided therapy technologies. For more information on how to apply, visit inovait.ca/funding. To learn more about Velacur and Sonic Incytes, visit sonicincytes.com.

Share this on social media

Learn more about the network

How 16 Bit harnessed AI to prevent costly fractures, one X-ray at a time

How 16 Bit harnessed AI to prevent costly fractures, one X-ray at a time

As with many transformative businesses, 16 Bit came to be because of, sure, the brilliance and vision of its founders, but also a great deal of serendipity. 16 Bit might not exist had Dr. Mark Cicero and Dr. Alexander Bilbily not both chosen to pursue medical school (with backgrounds in engineering and computer science, respectively), had they not both decided to specialize in radiology, and had they not ended up in the same residency training program at the University of Toronto.

INOVAIT reveals Canada’s strategic advantages in image-guided therapy and artificial intelligence in latest report

INOVAIT reveals Canada’s strategic advantages in image-guided therapy and artificial intelligence in latest report

INOVAIT, the pan-Canadian innovation network supporting advancements and commercialization in image-guided therapy (IGT) and artificial intelligence (AI), is excited to share their latest report titled, ‘Unlocking Medtech’s Potential: Canada’s Strategic Advantages in Image-Guided Therapy & AI’. Through synthesized insights from interviews with founders and executives from 30 IGT companies in the INOVAIT Network, this new report uncovers the untapped potential of the image-guided therapy sector in Canada.